XOMA Royalty Corp. Files Q1 2025 10-Q
Ticker: XOMAP · Form: 10-Q · Filed: May 13, 2025 · CIK: 791908
| Field | Detail |
|---|---|
| Company | Xoma Royalty Corp (XOMAP) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, royalty-agreements, pharmaceuticals
TL;DR
XOMA Royalty Corp Q1 2025 10-Q filed. Royalty deals with Dare & Aptevo detailed.
AI Summary
XOMA Royalty Corp. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business activities. Key events mentioned include royalty purchase agreements related to Sildenafil Cream and Ovaprene with Dare, and a commercial payment purchase agreement with Aptevo.
Why It Matters
This filing provides investors with an update on XOMA Royalty Corp.'s financial performance and operational developments for the first quarter of 2025, including details on royalty agreements.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial and operational updates.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 20250513 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- XOMA Royalty Corp. (company) — Filer
- Dare (company) — Counterparty in Royalty Purchase Agreements
- Sildenafil Cream (product) — Subject of Royalty Purchase Agreement
- Ovaprene (product) — Subject of Royalty Purchase Agreement
- Aptevo (company) — Counterparty in Commercial Payment Purchase Agreement
FAQ
What is the nature of the royalty purchase agreements with Dare?
The filing mentions royalty purchase agreements with Dare related to Sildenafil Cream and Ovaprene, with transactions occurring between April 1, 2024, and April 30, 2024.
What is the commercial payment purchase agreement with Aptevo?
XOMA Royalty Corp. entered into a commercial payment purchase agreement with Aptevo on October 1, 2024.
What is XOMA Royalty Corp.'s primary business?
XOMA Royalty Corp. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
When did XOMA Royalty Corp. change its name from XOMA Corp?
The company's name change from XOMA Corp occurred on January 19, 2012.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 13, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding XOMA Royalty Corp (XOMAP).